The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study.
The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study.
复制标题
DOI：
10.1016/j.jjcc.2022.03.015
复制
发表时间：
2022-10
影响因子：
2.5
通讯作者：
CLOT-COVID Study Investigators
中科院分区：
文献类型：
--
作者：
Nishimoto Y;Yachi S;Takeyama M;Tsujino I;Nakamura J;Yamamoto N;Nakata H;Ikeda S;Umetsu M;Aikawa S;Hayashi H;Satokawa H;Okuno Y;Iwata E;Ogihara Y;Ikeda N;Kondo A;Iwai T;Yamada N;Ogawa T;Kobayashi T;Mo M;Yamashita Y;CLOT-COVID Study Investigators
Data on thrombosis and current real-world management strategies for anticoagulation therapy are scarce but important for understanding current issues and unmet needs of an optimal management of patients with coronavirus disease 2019 (COVID-19). The CLOT-COVID Study (thrombosis and antiCoaguLatiOn Therapy in patients with COVID-19 in Japan Study: UMIN000045800) was a retrospective, multicenter cohort study enrolling consecutive hospitalized patients with COVID-19 among 16 centers in Japan from April 2021 to September 2021, and we tried to capture the status of the patients in the fourth and fifth waves of the COVID-19 infections in Japan. We enrolled consecutive hospitalized patients who were diagnosed with COVID-19 and had a positive polymerase chain reaction test obtained from the hospital databases. Among 2894 patients with COVID-19, 1245 (43%) received pharmacological thromboprophylaxis. The proportion of pharmacological thromboprophylaxis increased according to the severity of the COVID-19 in 9.8% with mild COVID-19, 61% with moderate COVID-19, and 97% with severe COVID-19. The types and doses of anticoagulants varied widely across the participating centers. During the hospitalization, 38 patients (1.3%) and 126 (4.4%) underwent ultrasound examinations for the lower extremities and contrast-enhanced computed tomography examinations, respectively, and 55 (1.9%) developed thrombosis, mostly venous thromboembolism (71%). The incidence of thrombosis increased according to the severity of the COVID-19 in 0.2% with mild COVID-19, 1.4% with moderate COVID-19, and 9.5% with severe COVID-19. Major bleeding occurred in 57 patients (2.0%) and 158 (5.5%) died, and 81% of them were due to respiratory failure from COVID-19 pneumonia. In the present large-scale observational study, pharmacological thromboprophylaxis for hospitalized patients with COVID-19 was common especially in patients with severe COVID-19, and management strategies varied widely across the participating centers. The overall incidence of thrombosis was substantially low with an increased incidence according to the severity of the COVID-19.
登录
查看更多内容
影响因子：
4.2
作者：
Kaptein FHJ;Stals MAM;Huisman MV;Klok FA
通讯作者：
Klok FA
影响因子：
2.1
作者：
Iba T;Connors JM;Spyropoulos AC;Wada H;Levy JH
通讯作者：
Levy JH
DOI：
10.1136/bmj.n2400
发表时间：
2021-10-14
期刊：
BMJ (Clinical research ed.)
影响因子：
--
作者：
Sholzberg M;Tang GH;Rahhal H;AlHamzah M;Kreuziger LB;Áinle FN;Alomran F;Alayed K;Alsheef M;AlSumait F;Pompilio CE;Sperlich C;Tangri S;Tang T;Jaksa P;Suryanarayan D;Almarshoodi M;Castellucci LA;James PD;Lillicrap D;Carrier M;Beckett A;Colovos C;Jayakar J;Arsenault MP;Wu C;Doyon K;Andreou ER;Dounaevskaia V;Tseng EK;Lim G;Fralick M;Middeldorp S;Lee AYY;Zuo F;da Costa BR;Thorpe KE;Negri EM;Cushman M;Jüni P;RAPID trial investigators
通讯作者：
RAPID trial investigators
DOI：
10.1016/j.jiac.2021.02.019
发表时间：
2021-06
期刊：
Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy
影响因子：
--
作者：
Fujiwara S;Nakajima M;Kaszynski RH;Fukushima K;Tanaka M;Yajima K;Kobayashi T;Sekiya N;Yamamoto Y;Miwa M;Ishihata A;Yamauchi Y;Yamamoto K;Goto H;Imamura A
通讯作者：
Imamura A
影响因子：
3.3
作者：
Sakamoto, Jiro;Yamashita, Yugo;Kimura, Takeshi
通讯作者：
Kimura, Takeshi